Celator(R) Pharmaceuticals Announces Publication of Positive Phase 2 Data With CPX-351 in Acute Myeloid Leukemia Patients

By: via Benzinga
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), announced the publication of the Phase 2 study evaluating CPX-351 in newly diagnosed ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.